These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 25712619)

  • 1. Chemotherapy- and irradiation-induced bone loss in adults with solid tumors.
    Wissing MD
    Curr Osteoporos Rep; 2015 Jun; 13(3):140-5. PubMed ID: 25712619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of bone metastases in prostate cancer: a review.
    Bienz M; Saad F
    Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
    von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
    Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches for protecting bone health in patients with breast cancer.
    Lüftner D; Niepel D; Steger GG
    Breast; 2018 Feb; 37():28-35. PubMed ID: 29073497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.
    Hendriks LE; Hermans BC; van den Beuken-van Everdingen MH; Hochstenbag MM; Dingemans AM
    J Thorac Oncol; 2016 Feb; 11(2):155-73. PubMed ID: 26718881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
    Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
    Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
    Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
    Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cancer treatment-induced bone loss. Treatment for breast cancer].
    Yamada K; Kohno N
    Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
    Gaudio A; Xourafa A; Rapisarda R; Castellino P
    Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer therapies and bone health.
    Hu MI; Lu H; Gagel RF
    Curr Rheumatol Rep; 2010 Jun; 12(3):177-85. PubMed ID: 20437119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
    Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
    Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
    Gralow J
    Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S54-62. PubMed ID: 15807925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
    Chukir T; Liu Y; Farooki A
    Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.
    Body JJ; von Moos R; Niepel D; Tombal B
    BMC Urol; 2018 Sep; 18(1):81. PubMed ID: 30236112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapies of bone disease with bisphosphonates.
    Syddall SP; Ottewell PD; Holen I
    Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of bone metastases].
    Nagykálnai T; Landherr L
    Orv Hetil; 2014 Feb; 155(6):217-25. PubMed ID: 24486845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab for cancer-related bone loss.
    Dell'Aquila E; Armento G; Iuliani M; Simonetti S; D'Onofrio L; Zeppola T; Madaudo C; Russano M; Citarella F; Ribelli G; Pantano F; Vincenzi B; Tonini G; Santini D
    Expert Opin Biol Ther; 2020 Nov; 20(11):1261-1274. PubMed ID: 32835531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.